Health Care

Analyze Natera Inc.’s CFO Brophy Burkes’ recent Rule 10b5‑1 sales—three trades at $425+, compliant, liquidity‑driven moves that signal confidence without hurting the stock’s long‑term outlook.

Azora Therapeutics’ CEO buys 232k shares amid rebrand, new ulcerative colitis trial, and private placement—insider confidence signals potential upside despite current volatility.

Insider selling spikes at PACS Group—chief accountants liquidate nearly $470K in shares above the market price, hinting at possible strategic shifts or cash needs.

Insightful breakdown of CEO Atay Oguzhan’s recent insider trades at BillionToOne – a disciplined Rule 10b5‑1 buy‑sell strategy that keeps ownership neutral while boosting liquidity and showing confidence in the company’s growth.

CEO Demopulos exercises 500k performance options, boosting insider confidence in OMEROS’s bullish run and long‑term growth prospects.

Analyze ANI Pharma’s 2026 insider sales: CFO’s controlled $72.87 trades show routine liquidity management, not a red‑flag, for mid‑cap investors.

ACME United insider moves reveal a balanced “buy low, sell high” strategy—Susan Murphy sells at a 52‑week peak, adds shares at a lower exercise price, signaling confidence and long‑term growth in the health‑care supply chain.

Inside BillionToOne’s recent Class A share moves, see how insider buying, selling, and non‑consideration transfers signal management confidence and investor implications.

Castle Biosciences insider sales reveal a disciplined cash‑management strategy, not a red flag, and suggest confidence in the company’s rising valuation.

Weber Darin J.’s insider purchase signals confidence in ProKidney’s regenerative kidney therapy and a potential price lift amid a new $200 M open‑market sale.